Nanochap raises CNY300 million in strategic financing
Legend Capital co-led the round, with proceeds supporting visual brain-computer interface trials and technology development.
Nanochap completed CNY300 million in strategic financing, according to a May 6, 2026 report by VCBeat. Legend Capital and an unnamed industrial investor co-led the round. Existing backer Harvest Capital reinvested, while GF Xinde and Caitong Capital participated. Qifeng Capital was the financial adviser.
The company planned to use the proceeds to advance clinical trials of its visual brain-computer interfaces and develop the underlying technology. Its approach combines internally developed chips, electrodes, implant packaging and signal-processing algorithms.
Nanochap was pursuing both retinal and cortical routes to artificial vision. At the time of the financing, its retinal system had started human clinical trials, while a prospective trial of the cortical system was planned for later in 2026. The two routes are intended for patients with different conditions affecting their remaining visual pathways.
Use of funds
Visual brain-computer interface clinical trials
Core technology development